Press Releases Items Per Page 102550 Year None202320222021202020192018201720162015201420132012201120102007 01.10.20 Syndax Pharmaceuticals Highlights 2020 Clinical and Corporate Outlook 12.10.19 Syndax Pharmaceuticals Announces Plans to Commence Phase 2 Expansion Cohort of SNDX-6352 for the Treatment of Chronic Graft Versus Host Disease 12.09.19 Syndax Announces Preclinical Results Supporting Development of its Portfolio of Menin Inhibitors In Mixed Lineage Leukemias 11.07.19 Syndax Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Clinical and Business Update 11.06.19 Syndax Announces First Patient Dosed in Phase 1/2 AUGMENT-101 Trial of SNDX-5613 for the Treatment of Adults with Relapsed/Refractory Acute Leukemias 10.31.19 Syndax to Announce Third Quarter 2019 Financial Results and Host Conference Call and Webcast on November 7, 2019 08.28.19 Syndax Announces Participation at Four Upcoming Investor Conferences 08.07.19 Syndax Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Clinical and Business Update 08.05.19 Syndax to Participate in the BTIG Biotechnology Conference 07.31.19 Syndax to Announce Second Quarter 2019 Financial Results and Host Conference Call and Webcast on August 7, 2019 07.10.19 Syndax Pharmaceuticals Announces FDA Clearance of IND Application for Targeted Menin Inhibitor SNDX-5613 for Relapsed/Refractory Acute Leukemias 06.13.19 Syndax to Present at the JMP Securities Life Sciences Conference Pagination First page « first Previous page ‹ previous … Page 4 Page 5 Page 6 Page 7 Current page 8 Page 9 Page 10 Page 11 Page 12 … Next page next › Last page last »
12.10.19 Syndax Pharmaceuticals Announces Plans to Commence Phase 2 Expansion Cohort of SNDX-6352 for the Treatment of Chronic Graft Versus Host Disease
12.09.19 Syndax Announces Preclinical Results Supporting Development of its Portfolio of Menin Inhibitors In Mixed Lineage Leukemias
11.07.19 Syndax Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Clinical and Business Update
11.06.19 Syndax Announces First Patient Dosed in Phase 1/2 AUGMENT-101 Trial of SNDX-5613 for the Treatment of Adults with Relapsed/Refractory Acute Leukemias
10.31.19 Syndax to Announce Third Quarter 2019 Financial Results and Host Conference Call and Webcast on November 7, 2019
08.07.19 Syndax Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Clinical and Business Update
07.31.19 Syndax to Announce Second Quarter 2019 Financial Results and Host Conference Call and Webcast on August 7, 2019
07.10.19 Syndax Pharmaceuticals Announces FDA Clearance of IND Application for Targeted Menin Inhibitor SNDX-5613 for Relapsed/Refractory Acute Leukemias